A randomized study of interferon α-2b versus no treatment as consolidation after high dose therapy and autologous stem cell transplantation for patients with relapsed lymphoma.
Authors
Bosly, AGrigg, A
Holte, H
Gisselbrecht, C
Radford, John A
Rossi, A
Lopez-Guillermo, A
Trneny, M
Sebban, C
Hagberg, H
Leal da Costa, F
Colombat, P
Bron, D
Coiffier, B
Issue Date
2013
Metadata
Show full item recordAbstract
Patients with lymphoma who have experienced a first relapse or progression and have disease deemed sensitive to salvage chemotherapy nevertheless have a high likelihood of having a second relapse. To decrease the likelihood of a second relapse after high-dose therapy (HDT) and autologous stem cell transplantation (ASCT), interferon (IFN) α-2b was given in a prospective randomized international trial. Methods. In this trial, 221 patients with varying histologic diagnoses (8 small lymphocytic, 37 follicular, 9 mantle, 90 diffuse large B-cell, 20 peripheral T-cell, 3 high-grade B-cell non-Hodgkin lymphoma, and 54 Hodgkin lymphoma) were randomly assigned to receive no further treatment (arm A: 117 patients) or IFNα-2b, 3 MU three times weekly, for 18 months (arm B: 104 patients). Results. In arm B, 21 patients (20%) did not receive IFNα-2b because of early progression or absence of hematologic recovery, 29 patients (28%) completed the 18 months of treatment, and 54 patients (52%) interrupted treatment because of progression (23%) or toxicity (29%). Event-free survival and overall survival were not different between the two arms on an intent-to-treat analysis and also if analysis was restricted to patients who were alive and had not experienced disease progression three months after transplantation. The study was not sufficiently powered to evaluate effects in histologic subtypes. Conclusion. In this trial, post-autograft IFNα-2b did not improve outcomes in a heterogeneous group of patients with lymphoma.Citation
A randomized study of interferon α-2b versus no treatment as consolidation after high dose therapy and autologous stem cell transplantation for patients with relapsed lymphoma. 2013, 18 (11):1189 OncologistJournal
The OncologistDOI
10.1634/theoncologist.2013-0223PubMed ID
24105750Type
ArticleLanguage
enISSN
1549-490Xae974a485f413a2113503eed53cd6c53
10.1634/theoncologist.2013-0223
Scopus Count
Collections
Related articles
- Myeloablative radiochemotherapy followed by autologous stem cell transplantation in first remission prolongs progression-free survival in follicular lymphoma: results of a prospective, randomized trial of the German Low-Grade Lymphoma Study Group.
- Authors: Lenz G, Dreyling M, Schiegnitz E, Forstpointner R, Wandt H, Freund M, Hess G, Truemper L, Diehl V, Kropff M, Kneba M, Schmitz N, Metzner B, Pfirrmann M, Unterhalt M, Hiddemann W, German Low-Grade Lymphoma Study Group
- Issue date: 2004 Nov 1
- High-dose therapy with autologous stem cell transplantation versus chemotherapy or immuno-chemotherapy for follicular lymphoma in adults.
- Authors: Schaaf M, Reiser M, Borchmann P, Engert A, Skoetz N
- Issue date: 2012 Jan 18
- Moderate increase of secondary hematologic malignancies after myeloablative radiochemotherapy and autologous stem-cell transplantation in patients with indolent lymphoma: results of a prospective randomized trial of the German Low Grade Lymphoma Study Group.
- Authors: Lenz G, Dreyling M, Schiegnitz E, Haferlach T, Hasford J, Unterhalt M, Hiddemann W
- Issue date: 2004 Dec 15
- High-dose chemotherapy and autologous stem cell transplant compared with conventional chemotherapy for consolidation in newly diagnosed primary CNS lymphoma--a randomized phase III trial (MATRix).
- Authors: Schorb E, Finke J, Ferreri AJ, Ihorst G, Mikesch K, Kasenda B, Fritsch K, Fricker H, Burger E, Grishina O, Valk E, Zucca E, Illerhaus G
- Issue date: 2016 Apr 21
- A randomized study comparing yttrium-90 ibritumomab tiuxetan (Zevalin) and high-dose BEAM chemotherapy versus BEAM alone as the conditioning regimen before autologous stem cell transplantation in patients with aggressive lymphoma.
- Authors: Shimoni A, Avivi I, Rowe JM, Yeshurun M, Levi I, Or R, Patachenko P, Avigdor A, Zwas T, Nagler A
- Issue date: 2012 Oct 1